Press Releases | Archives

December 21, 2015

Inviting outside investment in the business based on “Toshiba Revitalization Action Plan”

Toshiba Medical Systems Corporation (“TMSC”, President: Toshio Takiguchi; Headqurters: Otawara, Tochigi, Japan), has decided to work on inviting outside majority shareholder(s), in order to strengthen the financial ability to further realize our growth strategies, following the announcement of “Toshiba Revitalization Action Plan” by Toshiba Corporation.

December 1, 2015

New technology to project expansive virtual reality images inside the magnet bore -Reducing patient anxiety caused by the confined MRI examination space-

Toshiba Corporation and Toshiba Medical Systems Corporation have developed a technology for displaying expansive virtual reality images inside the bore*1 of MRI systems.

November 30, 2015

Toshiba Unveils First Fully Integrated, Easy-to-Use Model-Based Iterative Reconstruction

FIRST Technology Enhances Image Quality and Lowers Dose

November 29, 2015

Toshiba's Aquilion Lightning Lowers the Cost of Ownership for Entry-Level CT Systems

Toshiba is reducing the cost of CT system ownership with the launch of the all-new Aquilion LightningTM.

November 29, 2015

Toshiba Delivers Improved Workflow and Visualization with Ultrasound Enhancements

Innovation 2016 for Aplio 500 Platinum Series May Help Expand Detection and Diagnosis with Less Invasive Ultrasound Procedures

November 26, 2015

Release of Toshiba 1.5T MRI System Vantage Elan / eS Edition

Toshiba Medical Systems Corporation (President: Toshio Takiguchi; Headquarters: Otawara, Tochigi, Japan) has launched global sales of the Toshiba 1.5-tesla MRI system Vantage Elan™ / eS Edition (eS: exquisite Solution).

November 16, 2015

Signing an OEM Agreement with British Company OptiGene

Toshiba Medical Systems Corporation (headquarters: Otawara, Tochigi; president: Toshio Takiguchi) has signed an OEM agreement with British company OptiGene Limited (“OptiGene”; headquarters: Unit 5, Blatchford Road, Horsham, West Sussex RH13 5QR, United Kingdom; president: Michael Andreou) for its gene fluorescent detector that employs isothermal amplification (“Detector”) .

October 14, 2015

Release of Toshiba 3T MRI System Vantage Titan 3T with Latest Edition

Toshiba Medical SystemToshiba Medical Systems Corporation (President: Toshio Takiguchi; Headquarters: Otawara, Tochigi, Japan) has launched global sales of the Toshiba 3-tesla MRI system Vantage Titan™ 3T / iS Edition (iS: intelligent Solution).s Corporation (President: Toshio Takiguchi; Headquarters: Otawara, Tochigi, Japan) has launched global sales of the Toshiba 3-tesla MRI system Vantage Titan™ 3T / iS Edition (iS: intelligent Solution).

October 13, 2015

Olea Medical to join Toshiba Medical Systems Corporation Group

Toshiba Medical Systems Corporation (“Toshiba”) announced today that Toshiba has completed the acquisition of the outstanding shares of Olea Medical SA (“Olea”), following approval from the French Ministry of Economy.

October 2, 2015

FC Barcelona Appoints Toshiba Medical Systems As Official Medical Systems Partner

Toshiba Medical Systems Europe B.V. (headquarters: Zoetermeer, Netherlands; President: Hiroyuki Tachikawa, “TMSE”), which is a regional subsidiary of Toshiba Medical Systems Corporation (headquarters: Otawara, Tochigi Prefecture, Japan; President: Toshio Takiguchi, “TMSC”) signed a 5-year contract with FC Barcelona to be its official medical systems partner.

September 7, 2015

Establishment of Russia-Japan Cardiac Imaging Training Center - Assisting cardiac diagnostic imaging in Russia -

Medical Excellence JAPAN (MEJ; President: Shuzo Yamamoto MD) and Toshiba Medical Systems Corporation (TMSC; President: Toshio Takiguchi) have established the Russia-Japan Cardiac Imaging Training Center in cooperation with I.M. Sechenov First Moscow State Medical University (location: Moscow; Rector: Prof. Petr V. Glybochko) and A.L. Myasnikov Institute of Clinical Cardiology (location: Moscow; Director: Prof. Yevgeny I. Chazov). An opening ceremony will be held at the site at 11:00 a.m. on September 7.

July 1, 2015

Toshiba manufactures milestone 1000th 320-row area detector CT, Aquilion ONE.

Otawara, Japan, July 1st, 2015 — achieving a significant milestone in the advancement of computed tomography (CT) in the practice of diagnostic imaging, Toshiba Medical Systems Co., Ltd. (Headquarters: Tochigi Prefecture Otawara President: Takiguchi Toshio) announced the production of the 1000th Aquilion ONE™, launched in 2007 as the world’s first 320-row area detector CT, able to scan 16cm at once.

April 9, 2015

IBA and Toshiba Sign Strategic Partnership in Particle Therapy

Collaboration signed to enhance access to proton therapy and carbon therapy worldwide Toshiba Medical Systems Corporation to become IBA's Proteus®ONE distributor in Japan IBA to become Toshiba's carbon therapy agent outside of Japan

March 30, 2015

Release of Toshiba 1.5-T MRI System Vantage Titan™ With Latest Version of M-Power™ V3.1

Otawara, Japan, March 30, 2015 - Toshiba Medical Systems Corporation (President: Toshio Takiguchi; Headquarters: Otawara, Tochigi, Japan) has launched global sales of the Toshiba 1.5-tesla MRI system Vantage Titan™ with the latest version of the M-Power™ platform V3.1.

March 3, 2015

TOSHIBA INTRODUCES AQUILION LIGHTNING AT ECR 2015

Posted on February 16, 2015 by TMSE - Toshiba is pleased to announce the release of the Aquilion Lightning, a 16-row helical CT with the world's smallest detector element size of 0.5mm for routine isotropic imaging.

February 11, 2015

Toshiba Medical Systems Manufacturing Asia Sdn. Bhd. Officially Launched in Penang - Malaysia's First Diagnostic Imaging Systems Manufacturing Base Established by Toshiba Medical Systems Corporation -

Penang, Malaysia - Toshiba Medical Systems Manufacturing Asia Sdn. Bhd. (TMMA), a wholly-owned Malaysian subsidiary of Toshiba Medical Systems Corporation was officially launched today.

January 6, 2015

NON-CONTRAST RENAL MRA IS AN ACCURATE METHOD FOR DETECTING RENAL ARTERY STENOSIS: FINDINGS FROM A FIRST OF ITS KIND INTERNATIONAL NON-CONTRAST MRA MULTI-CENTER TRIAL RECENTLY PUBLISHED IN AJR (AMERICAN JOURNAL OF ROENTGENOLOGY)

Otawara, Japan, January 6, 2015 - In 2006, the Food and Drug Administration (FDA) released a public health advisory warning of the risk of developing nephrogenic systemic fibrosis (NSF) associated with the use of all gadolinium-containing contrast agents in patients with end stage renal disease or acute renal failure, as well as patients with chronic kidney disease.

Contact Us